Opus Genetics Inc. has completed a private placement transaction, issuing and selling a total of 3,138,338 shares of its common stock to certain investors for approximately $3.5 million. The transaction, which closed on August 25, 2025, was led by Cam Gallagher, Chair of the Company's board of directors, with an investment of $1.0 million, and included participation by Sean Ainsworth, the lead independent director, among other investors. The shares were sold under exemptions from registration provided by the Securities Act.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-032533), on August 25, 2025, and is solely responsible for the information contained therein.